Millennium Management LLC raised its stake in Audentes Therapeutics Inc (NASDAQ:BOLD) by 49.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 773,279 shares of the biotechnology company’s stock after buying an additional 255,086 shares during the quarter. Millennium Management LLC’s holdings in Audentes Therapeutics were worth $21,721,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Meeder Asset Management Inc. raised its holdings in shares of Audentes Therapeutics by 578.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 619 shares during the period. Aperio Group LLC purchased a new stake in shares of Audentes Therapeutics in the second quarter valued at about $46,000. Tower Research Capital LLC TRC grew its holdings in shares of Audentes Therapeutics by 1,137.6% in the third quarter. Tower Research Capital LLC TRC now owns 2,438 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 2,241 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Audentes Therapeutics by 50.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 1,005 shares during the period. Finally, Bank of Montreal Can increased its position in Audentes Therapeutics by 810.4% during the second quarter. Bank of Montreal Can now owns 4,106 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 3,655 shares during the last quarter. Institutional investors own 98.08% of the company’s stock.
In other Audentes Therapeutics news, Director Louis G. Lange sold 10,000 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the transaction, the director now directly owns 276,044 shares in the company, valued at $8,877,575.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew R. Patterson sold 14,426 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $30.00, for a total value of $432,780.00. Following the transaction, the chief executive officer now owns 127,820 shares in the company, valued at $3,834,600. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.
Shares of BOLD stock opened at $28.61 on Tuesday. The firm has a market cap of $1.33 billion, a PE ratio of -8.41 and a beta of 1.77. The company has a 50-day moving average of $27.71 and a two-hundred day moving average of $33.11. Audentes Therapeutics Inc has a 1-year low of $17.95 and a 1-year high of $41.65.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.07. During the same quarter last year, the firm earned ($0.97) EPS. As a group, sell-side analysts anticipate that Audentes Therapeutics Inc will post -4.13 EPS for the current fiscal year.
BOLD has been the topic of a number of analyst reports. Robert W. Baird began coverage on shares of Audentes Therapeutics in a research note on Wednesday, October 2nd. They set an “underperform” rating and a $10.00 target price on the stock. BidaskClub cut shares of Audentes Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $48.00 price target on shares of Audentes Therapeutics in a report on Friday, November 8th. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Audentes Therapeutics in a research report on Sunday, October 6th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. Audentes Therapeutics presently has a consensus rating of “Hold” and an average price target of $42.00.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Story: Why do company’s buyback their stock?
Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.